Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Expands By 61.2%

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 81,743 shares, an increase of 61.2% from the December 15th total of 50,720 shares. Approximately 3.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 72,259 shares, the days-to-cover ratio is presently 1.1 days. Based on an average daily trading volume, of 72,259 shares, the days-to-cover ratio is presently 1.1 days. Approximately 3.7% of the shares of the stock are short sold.

Dogwood Therapeutics Stock Performance

NASDAQ:DWTX opened at $2.80 on Friday. The stock’s 50 day moving average price is $5.22 and its 200 day moving average price is $5.26. Dogwood Therapeutics has a 52 week low of $1.87 and a 52 week high of $29.28. The company has a market capitalization of $6.41 million, a P/E ratio of -0.11 and a beta of 1.90.

Dogwood Therapeutics (NASDAQ:DWTX) last posted its earnings results on Thursday, November 6th. The company reported ($8.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($6.97). As a group, sell-side analysts forecast that Dogwood Therapeutics will post -6.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DWTX has been the subject of several research reports. Wall Street Zen lowered Dogwood Therapeutics to a “strong sell” rating in a research note on Saturday, December 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Monday, December 22nd. Finally, HC Wainwright lifted their target price on Dogwood Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, September 30th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dogwood Therapeutics has a consensus rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.